Cala Health, the bioelectronic medicine leader setting a new standard of patient care for chronic disease, today announced $77 million in new financing led by Ascension Ventures. New investors Dolby Family Ventures; PEAK6 Strategic Capital, a division of PEAK6 Investments; and Innovatus Capital Partners joined the round as did all existing investors. The funds will help Cala Health expand patient access and accelerate innovation, opening opportunities to explore indications beyond essential tremor, including other neurological indications like Parkinson's disease as well as targets in psychiatry, cardiology and autoimmune disorders.

Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its vertically integrated commercial model is reshaping the delivery of prescription therapies. Cala Health's lead product, Cala Trio™, is the only non-invasive prescription therapy for essential tremor. New therapies are under development in Parkinson's disease and other indications in neurology, as well as targets in psychiatry, cardiology and autoimmune disorders. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.